雷贝拉唑、呋喃唑酮联合阿莫西林、枸橼酸铋钾四联疗法根治慢性胃炎伴Hp感染

Rabeprazole, Furazolidone Combined with Amoxicillin and Bismuth Potassium Citrate Quadruple Therapy for Chronic Gastritis with Hp Infection

目的:探讨雷贝拉唑、呋喃唑酮联合阿莫西林、枸橼酸铋钾四联疗法,在根治慢性胃炎伴幽门螺杆菌(Hp)感染中的应用效果。方法:2017年5月至2019年5月,将60例门诊慢性胃炎伴Hp感染患者作为研究对象,按照随机数表法将其分为对照组30例(雷贝拉唑、阿莫西林、克拉霉素、枸橼酸铋钾)四联疗法;观察组30例(雷贝拉唑、呋喃.唑酮联合阿莫西林、枸橼.酸铋钾)四.联疗法。对比两组患者的治疗效果以及不良反应情.况。结果:治疗后,对照组患者临床治疗有效率为8667%,明显低于观察组10000%(P<005)。对比两组患者不良反应发生率差异显著(P<005)。结论:通过对慢性胃炎伴Hp感染患者,采用雷贝拉唑、呋喃唑酮联合阿莫西林、枸橼酸铋钾四联疗法,能够起到显著的治疗效果,同时也减少了不良反应的发生,临床应用价值及临床推广极高。

Objective: To investigate the effect of rabeprazole, furazolidone combined with amoxicillin and bismuth potassium citrate in the treatment of chronic gastritis with Hp infection. Methods: From May 2017 to May 2019, 60 patients with chronic gastritis and Hp infection were enrolled in the study. According to the random number table method, 30 patients were divided into the control group(Riberazole, Amoxicillin, Carat Tetramycin, bismuth potassium citrate) quadruple therapy;observation group 30 cases(rebeprazole, furazolidone combined with amoxicillin, bismuth potassium citrate) quadruple therapy. The treatment effect and adverse reactions of the two groups of patients were compared. Results: After treatment, the clinical effective rate of the control group was 86.67%, which was significantly lower than that of the observation group(100.00%)(P<0.05). The incidence of adverse reactions was significantly different between the two groups(P<0.05). Conclusion: By treating patients with chronic gastritis with Hp infection, rabeprazole, furazolidone combined with amoxicillin and bismuth potassium citrate can achieve significant therapeutic effects and reduce adverse reactions. Application value and clinical promotion are extremely high.